Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice

Oncology Research

Volumn 10, Issue 10, 1998, Pages 533-539

  Andrei, G ^a   Snoeck, R ^a   Piette, J ^b   Delvenne, P ^c   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Laboratory of Fundamental Virology   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cervical carcinoma; Cidofovir; Papillomavirus

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CYTOSINE; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DOSE RESPONSE; FEMALE; HUMAN; MOUSE; NUDE MOUSE; TIME; UTERINE CERVIX TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 0032250518     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. zur Hausen, H. Viruses in human cancer. Science 254:1167-1173; 1991.
2. Steele, C.;Shillitoe, E. J. Viruses and oral cancer. Crit. Rev. Oral Biol. Med. 2:153-175; 1991.
3. Koutsky, L. A.;Galloway, D. A.;Holmes, K. K. Epidemiology of genital human papillomavirus infection. Epidemiol. Rev. 10:122-162; 1988.
4. zur Hausen, H. Human papillomavirus in pathogenesis of anogenital cancer.Virology 184:9-13; 1991.
5. Schiffman, M. H. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J. Natl. Cancer Inst. 84:394-397; 1992.
6. Yee, C.;Krishnan-Hewlett, I.;Baker, C. C.;Sehlegel, R.;Howley, P. M. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.Am. J. Pathol. 119:361-366; 1985.
7. Schwarz, E.;Freese, U. K.;Gissmann, L.;Mayer, W.;Roggenberck, B.;Stremlau, A.;zur Hausen, H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111-114; 1985.
8. de Villers, E. M. Heterogeneity of the human papillomavirus group.J. Virol. 63:4898-4903; 1989.
9. Shah, K. V.;Howley, P. M. Papillomaviruses. In:Fields, B. N.;Knipe, D. M.;Howley, P. M., eds. Field virology, vol. 2. Philadelphia: Lippincott-Raven; 1996:2077-2109.
10. Hitchcock, M. J. M.;Jaffe, H. S.;Martin, J. C.;Stagg, R. J. Cidofovir, a new agent with potent anti-herpesvirus activity.Antiviral Chem. Chemother. 7:115-127; 1996.
11. Naesens, L.;Snoeck, R.;Andrei, G.;Balzarini, J.;Neyts, J.;De Clercq, E. HPMPC (cidofovir), PMEA (adefovir) and related ayclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections.Antiviral Chem. Chemother. 8:1-23; 1997.
12. Safrin, S.;Cherrington, J.;Jaffe, H. S. Clinical uses of cidofovir. Rev. Med. Virol. 7:145-156; 1997.
13. Kurtzman, G.;Pickel, M.;Christensen, N.;Kreider, J. Phosphonate nucleoside analogs are potent anti-papillomavirus agents in animal models. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orlean, 17-20 October, 1993 (Abstract 1593).
14. Snoeck, R.;Wellens, W.;Desloovere, C.;Van Ranst, M.;Naesens, L.;De Clercq, E.;Feenstra, L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine].J. Med. Virol. 54:219-225; 1998.
15. Van Cutsem, E.;Snoeck, R.;Van Ranst, M.;Fiten, P.;Opdenakker, G.;Geboes, K.;Janssens, J.;Rutgeerts, P.;Vantrappen, G.;De Clercq, E. Successful treatment of a squamous papilloma of the hypopharynx esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.J. Med. Virol. 45: 230-235; 1995.
16. Snoeck, R.;Van Ranst, M.;Andrei, G.;De Clercq, E.;De Wit, S.;Poncin, M.;Clumeck, N. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue.N. Engl. J. Med. 333:943-944; 1995.
17. Snoeck, R.;Bossens, M.;Parent, D.;Delaere, B.;De Greef, H.;De Clercq, E.;Safrin, S.;McGuire, B.;Jaffe, H.S. A double-blind, placebo-controlled study of cidofovir gel for human papillomavirus (HPV)-associated genital warts. Eleventh International Conference on Antiviral Research, San Diego, April, 1998 (Abstract 27).
18. Douglas, J.;Schacker, T.;Tyring, S.;Kriesel, J.;Bowden, B.;Crosbyn D.;Berger, T.;Conant, M.;McGuire, B.;Jaffe, H. S. A phase I/II study of cidofovir topical gel for refractory anogenital condyloma acuminatum in patients with HIV infection. 55th Annual Meeting of the American Association of Dermatology, San Francisco, 21-26 March, 1997 (Abstracts).
19. Andrei, G.;Snoeck, R.;Piette, J.;Delvenne, P.;De Clercq, E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPN)-harboring cell lines compared with HPV-negative cell lines.Oncol. Res. 10:523-531; 1998.
20. Ambros, R. A.;Kurman, R. J. Current concepts in the relationship of human papillomavirus infection to the pathogenesis and classification of precancerous squamous lesions of the uterine cervix.Semin. Diagn. Pathol. 7:158-172; 1990.
21. Phelps, W. C.;Alexander, K. A. Antiviral therapy for human papillomavirus: Rationale and prospects.Ann. Intern. Med. 123:368-382; 1995.
22. Kraus, S. J.;Stone, K. M. Management of genital infection caused by human papillomavirus.Rev. Infect. Dis. 12(Suppl. 6):S620-S632; 1990.
23. Beutner, K. R. Human papillomavirus infection. J. Am. Dermatol. 20:114-123; 1989.
24. Snoeck, R.;Arens, M.;Muller, C.;Noel, J. C.;De Clercq, E.;Bossens, M. Preliminary results on the activity of cidofovir for the treatment of cervical intraepithelial neoplasia (CIN) grade III. Tenth International Conference on Antiviral Research, Atlanta, 1997 (Abstract 108).
25. Barbosa, M. S.;Schlegel, R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in-vitro transformation of human keratinocytes.Oncogene 4:1529-1532; 1989.
26. Hawley-Nelson, P.;Vousden, K. H.;Hubbert, N. L.;Lowy, D. R.;Schiller, J. T. HPV16 E6 and E7 proteins cooperate to immortalize primary human foreskin keratinocytes.EMBO J. 8:3905-3910; 1989.
27. Hudson, J. B.;Bedell, M. A.;McCance, D. J.;Laimins, L. A. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18.J. Virol. 64:519-526; 1990.
28. Kaur, P.;McDougall, J. K.;Cone, R. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 open reading frames.J. Gen. Virol. 70:1261-1266; 1989.
29. Durst, M.;Gallahan, D.;Jay, G.;Rhim, J. S. Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene.Virology 173:767-771; 1989.
30. Chesters, P. M.;McCance, D. J. Human papillomavirus types 6 and 16 in cooperation with Ha-ras transform secondary rat embryo fibroblasts.J. Gen. Virol. 70:353-365; 1989.
31. Cihlar, T.;Chen, M. S. Identification of enzymes catalyzing twostep phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells.Mol. Pharmacol. 50: 1502-1510; 1996.
32. Xion, X.;Smith, J. L.;Kim, C.;Huang, E.;Chen, M. S. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase on DNA elongation.Biochem. Pharmacol. 51:1563-1567; 1996.
33. Baker, C. C.;Phelps, W. C.;Lindgren, V.;Braun, M. J.;Gonda, M. A.;Howleyn, P. M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines.J. Virol. 61:962-971; 1987.
34. Bolwell, B. J.;Cassileth, P. A.;Gale, R. P. High dose cytarabine: A review.Leukemia 2:253-260; 1988.
35. Manome, Y.;Wen, P. Y.;Dong, Y.;Tanaka, T.;Mitchell, B. S.;Kufe, D. W.;Fine, H. A. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat. Med. 2:467-573; 1996.
36. Hapke, D. M.;Stegmann, A. P.;Mitchell, B. S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.Cancer Res. 56:2343-2347; 1996.